Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Animal Health Division of Bayer HealthCare and Juvaris BioTherapeutics have executed a broad-based licensing agreement pursuant to which Bayer HealthCare will have complete access in the veterinary field to the Juvaris mono-immunotherapy and vaccine technology, which is being developed by Juvaris for human health care.
Subscribe to our email newsletter
The companies will evaluate and execute product development programs directed at immune stimulation and disease prevention in a variety of animal species. In addition, the agreement anticipates that Bayer Animal Health will help financially support Juvaris’s research, product formulation, development and GMP manufacturing activities to support its alliance obligations. The license is worldwide in scope.
Lykele van der Broek, president of Animal Health Division, Bayer, said: “The beauty about this cooperation is, that it is not just about one single product. It serves as a platform technology that helps us develop a wide range of applications in several species for numerous indications in preventing infectious diseases. This technology in combination with our in-house expertise dramatically expands our ability to develop new and innovative products that promote immune stimulation and disease prevention.”